Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abvc Biopharma (ABVC) EBIT Margin (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed EBIT Margin for 12 consecutive years, with 52719.04% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin rose 8855647.0% year-over-year to 52719.04%, compared with a TTM value of 1673.18% through Dec 2025, down 74984.0%, and an annual FY2025 reading of 22503.1%, down 2157976.0% over the prior year.
  • EBIT Margin was 52719.04% for Q4 2025 at Abvc Biopharma, up from 246.79% in the prior quarter.
  • Across five years, EBIT Margin topped out at 52719.04% in Q4 2025 and bottomed at 235539.83% in Q1 2024.
  • Average EBIT Margin over 5 years is 15917.38%, with a median of 1110.15% recorded in 2023.
  • The sharpest move saw EBIT Margin crashed -23405379bps in 2024, then soared 23583478bps in 2025.
  • Year by year, EBIT Margin stood at 17059.12% in 2021, then tumbled by -103bps to 531.92% in 2022, then plummeted by -4345bps to 23641.34% in 2023, then plummeted by -52bps to 35837.44% in 2024, then soared by 247bps to 52719.04% in 2025.
  • Business Quant data shows EBIT Margin for ABVC at 52719.04% in Q4 2025, 246.79% in Q3 2025, and 1773.38% in Q2 2025.